The FDA has given Illumina approval for its Extended RAS Panel for use on its MiSeqDx system. The test, which is expected to start shipping in the third quarter, helps determine whether patients with metastatic colorectal cancer will respond to Amgen's Vectibix by evaluating 56 variants in the NRAS and KRAS genes.
FDA OKs Illumina's Vectibix companion Dx on MiSeqDx system
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.